{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Epoch', 'Epoch 001', 'Type of contact', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'Visit', 'Time point', 'Pre-Month 0', 'Month 0', 'Month 6', 'Month 12', 'Blood samples for biomarkers', 'Record Adverse Events (AEs)*', 'A', 'Record serious adverse events (SAEs)', 'A', 'Screening conclusion', 'Study conclusion', 'HRQOL questionnaires:', 'CAT', 'O', 'O', 'O', 'SGRQ-C', 'O', 'O', 'O', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'O is used to indicate a study procedure that does not require documentation in the individual eCRF.', 'a For non-eligible subjects, only informed consent, inclusion/ exclusion criteria, demographic data and SAEs related to', \"study participation that occurred after signing the informed consent pages need to be completed in the subject's eCRF.\", 'For other activities, \"not done\\' can be indicated.', 'b', 'Record both documented and self-reported, non-documented AECOPD. Subjects need documentation for at least', '1', 'moderate or severe AECOPD within the previous year to be eligible for study participation.', 'C', 'Significant comorbidities include weight loss, cardiovascular disease, hypertension, gastro-oesophageal reflux', 'disease, osteoporosis/ osteopenia, skeletal muscle wasting and dysfunction, anxiety/ depression and diabetes.', 'd To be recorded in the \"Physical examination\\' section of the eCRF.', 'e Only study certified site staff can perform spirometry assessment.', 'f Only if no chest X-ray is taken within the previous 3 months.', 'g Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', '* Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'h Physical examination (Visit1-3) should be done only if necessary by the investigator or delegate.', '19-OCT-2018', '42', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 5 presents the list of study procedures for AECOPD visits.', 'Table 5', 'List of study procedures for AECOPD visits', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'within 96 hours of onset', 'at least every 2 weeks as of', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedi', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'Chest X-rays/pneumonia confirmationi', 'Confirm AECOPD and record its start date', 'Record current medication for AECOPD', 'Record healthcare resource utilisation', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Sputum samplingk', 'HRQOL questionnaire:', 'CAT', 'O', 'Record AECOPD severitym', 'Record AECOPD end date', 'Record Adverse Events (AEs)*', 'Record serious adverse events (SAEs)^', 'is used to indicate a study procedure that requires documentation in the individual eCRF.', 'i', 'End of AECOPD phone calls/ visits should be scheduled at least every 2 weeks, until the AECOPD has resolved. Only', 'the last phone call will be recorded in the eCRF as the end of the AECOPD phone call. All intermediate calls should be', 'recorded on source documentation.', 'j', 'Only if clinically indicated to exclude another cause of worsening of symptoms (e.g. pneumonia). If a chest X-ray is', 'clinically indicated but a chest X-ray/ CT scan has already been taken for that AECOPD as part of medical care before', 'the study AECOPD visit takes places, the results of that chest X-ray/ CT scan can be used. All cases of pneumonia', '(including all signs and symptoms assessed to confirm pneumonia) should be documented in the eCRF.', 'k', 'Sputum can be collected spontaneously or can be induced, as per investigator judgement. Sputum sampling should', 'only be done if, in the opinion of the investigator, it is safe for the subject.', 'I Physical examination should be done only if necessary by the investigator or delegate.', 'm AECOPD severity grading as indicated in Table 2.', '* Non-serious AEs will be recorded in the eCRF and will not be entered into the safety database.', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'Table 6 presents the intervals between study visits.', 'Table 6', 'Intervals between study visits', 'Interval', 'Optimal length of interval', 'Allowed interval\u00b9', 'Screening Visit (pre-Month 0)', 'Visit 1', '+ 14 days', '<42 days before Visit 1', 'Scheduled study visits', 'Visit 1 (Month 0)', 'Visit 2 (Month 6)', '182 days', '175 203 days', 'Visit 2 (Month 6)', 'Visit 3 (Month 12)', '182 days', '175 203 days', 'AECOPD-driven study visit(s) and/or phone contacts', 'Onset AECOPD symptoms', 'AECOPD Visit', 'max 96 hours\u00b2', '1 If an AECOPD occurs at the time one of the scheduled study visits is planned, the stable study visit should be re-', 'scheduled to a later date, when the subject is stable again and within the time window specified. In consultation with', 'GSK, the concluding visit (Visit 3, Month 12) may however exceptionally be conducted outside of the allowed interval if', 'necessary by the investigator.', '2 AECOPD visits will be scheduled as soon as possible after the onset of AECOPD symptoms as recorded in the', 'electronic Diary Card or confirmed by the subject (maximum 96 hours after and, if applicable, preferably before starting', 'treatment with antibiotics).', '19-OCT-2018', '43', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}